Market Cap (In INR)
1.45 Billion
Revenue (In INR)
1.04 Billion
Net Income (In INR)
-217.3 Million
Avg. Volume
24.39 Thousand
- Currency
- INR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 19.0-40.95
- PE
- -
- EPS
- -
- Beta Value
- 0.52
- ISIN
- INE670X01014
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dr. Omkar Pravin Herlekar
- Employee Count
- -
- Website
- https://lasalabs.com
- Ipo Date
- Details
- Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use comprising potassium iodide. It also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
More Stocks
-
STEW
-
WDAM
-
4428sinops Inc.
4428
-
4971
-
KPL
-
AKM
-
8354
-
9110